A Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients With Traumatic Brain Injury
Traumatic Brain Injury
Enrolment: 46 · Results not recorded
Loading the evidence…
Biologic
2 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Traumatic Brain Injury
Enrolment: 46 · Results not recorded
Subarachnoid Hemorrhage · Intracranial Aneurysm · Delayed Cerebral Ischemia · Delayed Ischemic Neurological Deficit
Enrolment: 50 · Results not recorded
Stroke
Enrolment: 80 · Results not recorded
Stroke
Enrolment: 119 · Results not recorded
Stroke, Ischemic · Stroke, Acute · Stroke Sequelae
Enrolment: 50 · Results not recorded
Covid19 Related Anosmia and Aguesia
Enrolment: 250 · Results not recorded
Chronic Stroke · Subacute Stroke
Enrolment: 4 · Results not recorded
Acute Ischemic Stroke
Enrolment: 100 · Results not recorded
Acute Ischemic Stroke
Enrolment: 1851 · Results not recorded
Cognitive Impairment
Enrolment: 500 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Impact acceleration-induced closed head injury
Cerebrolysin improved all functional outcomes at 14 days, increased neurons and neuroblasts in the dentate gyrus, preserved axonal integrity in the striatum, increased perfused vessels and VEGF-positive cells and reduced MMP-9 staining, although MMP-9 and VEGF mRNA did not differ at 48 hours.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.